Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 787 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo three times daily Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

NCT00073021
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
54
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

NCT06219915
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1, Placebo 2
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

NCT00623649
View directory record Official record
Conditions
HCV Infection
Interventions
VCH 916, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Echinacea Purpurea and Osteopathy in Children With Recurrent Otitis Media

NCT00689468
View directory record Official record
Conditions
Otitis Media
Interventions
Cranial osteopathic manipulative treatment., Echinacea purpurea, Sham osteopathic manipulative treatment, "Echinacea purpurea" placebo
Procedure · Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
12 Months to 60 Months
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
3
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 2, 2008 · Synced Sep 26, 2026, 3:43 PM EDT
Recruiting Phase 2 Interventional

Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression

NCT06263660
View directory record Official record
Conditions
Depression
Interventions
Keto-like supplement, Placebo
Dietary Supplement
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 4 Interventional

Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program

NCT01271218
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Diet, Exercise
Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

NCT00297180
View directory record Official record
Conditions
Obesity
Interventions
GW869682
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
3
States / cities
Daytona Beach, Florida • Baton Rouge, Louisiana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment

NCT00489255
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tigan®, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy

NCT02232893
View directory record Official record
Conditions
Postoperative Ileus
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Weston, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Naltrexone, Placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Baclofen on Marijuana Withdrawal and Relapse

NCT00373295
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Baclofen, Marijuana, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 4 Interventional Results available

Effects of Ranolazine and Exercise on Daily Physical Activity Trial

NCT01948310
View directory record Official record
Conditions
Chronic Stable Angina
Interventions
Ranolazine, Aerobic Exercise, Placebo
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 26, 2026, 3:43 PM EDT
Not listed Not applicable Interventional

Comparing Cognitive Remediation Approaches for Schizophrenia

NCT04123223
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cognitive Remediation, Computer Games
Behavioral
Lead sponsor
Wesleyan University
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Hartford, Connecticut • Middletown, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 26, 2026, 3:43 PM EDT
Terminated Phase 2 Interventional Results available

Interventional Bioremediation of Microbiota in Metabolic Syndrome

NCT02730962
View directory record Official record
Conditions
Pre-Diabetes
Interventions
Vancomycin, Placebo, Neomycin, Clindamycin, Fecal Microbiota Transplantation
Drug · Other · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 26, 2026, 3:43 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)

NCT04493320
View directory record Official record
Conditions
Depression, Cognitive Impairment, Gait Impairment
Interventions
Carbidopa/levodopa, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 26, 2026, 3:43 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Seaweed-derived Rhamnan Sulfate and Vascular Function

NCT05651230
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Rhamnan sulfate
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
35 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Not applicable Interventional Results available

Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)

NCT00644423
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Omega-3 Fatty Acid, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 26, 2026, 3:43 PM EDT
Recruiting Phase 2 Interventional

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

NCT05138575
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate, Potassium Chloride + Placebo for Empagliflozin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 26, 2026, 3:43 PM EDT
Not listed Phase 2 Interventional

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

NCT00281502
View directory record Official record
Conditions
Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis
Interventions
Rifaximin (drug)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 2 Interventional

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

NCT02424708
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reduced Glutathione 100mg, Reduced Glutathione 200mg, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Kenmore, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 26, 2026, 3:43 PM EDT
Not listed Phase 4 Interventional

Riociguat for Sarcoidosis Associated Pulmonary Hypertension

NCT02625558
View directory record Official record
Conditions
Sarcoidosis
Interventions
Riociguat, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335
View directory record Official record
Conditions
Head and Neck Neoplasms, Mucositis
Interventions
Brilacidin, Placebo
Drug · Other
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 26, 2026, 3:43 PM EDT
Completed Phase 2 Interventional Results available

A Study of Siliphos in Adults With Non-alcoholic Steatohepatitis (NASH)

NCT00443079
View directory record Official record
Conditions
Fatty Liver
Interventions
IdB 1016 (Siliphos), Matched placebo
Drug
Lead sponsor
Heather Patton
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 26, 2026, 3:43 PM EDT